269 related articles for article (PubMed ID: 7629743)
1. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system.
Bazile D; Prud'homme C; Bassoullet MT; Marlard M; Spenlehauer G; Veillard M
J Pharm Sci; 1995 Apr; 84(4):493-8. PubMed ID: 7629743
[TBL] [Abstract][Full Text] [Related]
2. Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel.
Ruan G; Feng SS
Biomaterials; 2003 Dec; 24(27):5037-44. PubMed ID: 14559017
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers.
Gref R; Quellec P; Sanchez A; Calvo P; Dellacherie E; Alonso MJ
Eur J Pharm Biopharm; 2001 Mar; 51(2):111-8. PubMed ID: 11226817
[TBL] [Abstract][Full Text] [Related]
4. Cell interaction studies of PLA-MePEG nanoparticles.
Nguyen CA; Allémann E; Schwach G; Doelker E; Gurny R
Int J Pharm; 2003 Mar; 254(1):69-72. PubMed ID: 12615412
[TBL] [Abstract][Full Text] [Related]
5. Gadolinium-conjugated PLA-PEG nanoparticles as liver targeted molecular MRI contrast agent.
Chen Z; Yu D; Liu C; Yang X; Zhang N; Ma C; Song J; Lu Z
J Drug Target; 2011 Sep; 19(8):657-65. PubMed ID: 21091273
[TBL] [Abstract][Full Text] [Related]
6. ABA and BAB type triblock copolymers of PEG and PLA: a comparative study of drug release properties and "stealth" particle characteristics.
He G; Ma LL; Pan J; Venkatraman S
Int J Pharm; 2007 Apr; 334(1-2):48-55. PubMed ID: 17116377
[TBL] [Abstract][Full Text] [Related]
7. [Characterization of Me. PEG-PLA copolymer nanoparticles prepared by modified spontaneous emulsion-solvent evaporation].
Dong J; Liu MX; Yang YJ; Xu HB; Yang XL
Yao Xue Xue Bao; 2004 Sep; 39(9):677-80. PubMed ID: 15606012
[TBL] [Abstract][Full Text] [Related]
8. Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density.
Essa S; Rabanel JM; Hildgen P
Int J Pharm; 2011 Jun; 411(1-2):178-87. PubMed ID: 21458551
[TBL] [Abstract][Full Text] [Related]
9. Preparation and biodisposition of methoxypolyethylene glycol amine-poly(DL-lactic acid) copolymer nanoparticles loaded with pyrene-ended poly(DL-lactic acid).
Sasatsu M; Onishi H; Machida Y
Int J Pharm; 2008 Jun; 358(1-2):271-7. PubMed ID: 18448290
[TBL] [Abstract][Full Text] [Related]
10. Intranasal delivery of zidovudine by PLA and PLA-PEG blend nanoparticles.
Mainardes RM; Khalil NM; Gremião MP
Int J Pharm; 2010 Aug; 395(1-2):266-71. PubMed ID: 20580792
[TBL] [Abstract][Full Text] [Related]
11. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption.
Gref R; Lück M; Quellec P; Marchand M; Dellacherie E; Harnisch S; Blunk T; Müller RH
Colloids Surf B Biointerfaces; 2000 Oct; 18(3-4):301-313. PubMed ID: 10915952
[TBL] [Abstract][Full Text] [Related]
12. MPEO-PLA nanoparticles: effect of MPEO content on some of their surface properties.
Zambaux MF; Bonneaux F; Gref R; Dellacherie E; Vigneron C
J Biomed Mater Res; 1999 Jan; 44(1):109-15. PubMed ID: 10397910
[TBL] [Abstract][Full Text] [Related]
13. In vitro macrophage uptake and in vivo biodistribution of long-circulation nanoparticles with poly(ethylene-glycol)-modified PLA (BAB type) triblock copolymer.
Shan X; Liu C; Yuan Y; Xu F; Tao X; Sheng Y; Zhou H
Colloids Surf B Biointerfaces; 2009 Sep; 72(2):303-11. PubMed ID: 19450955
[TBL] [Abstract][Full Text] [Related]
14. In vitro macrophage uptake and in vivo biodistribution of PLA-PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content.
Sheng Y; Yuan Y; Liu C; Tao X; Shan X; Xu F
J Mater Sci Mater Med; 2009 Sep; 20(9):1881-91. PubMed ID: 19365612
[TBL] [Abstract][Full Text] [Related]
15. Preparation of nanoparticles consisted of poly(L-lactide)-poly(ethylene glycol)-poly(L-lactide) and their evaluation in vitro.
Matsumoto J; Nakada Y; Sakurai K; Nakamura T; Takahashi Y
Int J Pharm; 1999 Aug; 185(1):93-101. PubMed ID: 10425369
[TBL] [Abstract][Full Text] [Related]
16. Preparation of a PLA-PEG block copolymer using a PLA derivative with a formyl terminal group and its application to nanoparticulate formulation.
Sasatsu M; Onishi H; Machida Y
Int J Pharm; 2005 Apr; 294(1-2):233-45. PubMed ID: 15814247
[TBL] [Abstract][Full Text] [Related]
17. Poly-DL-lactic acid: polyethylene glycol block copolymers. The influence of polyethylene glycol on the degradation of poly-DL-lactic acid.
Shah SS; Zhu KJ; Pitt CG
J Biomater Sci Polym Ed; 1994; 5(5):421-31. PubMed ID: 8038137
[TBL] [Abstract][Full Text] [Related]
18. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density.
Vila A; Gill H; McCallion O; Alonso MJ
J Control Release; 2004 Aug; 98(2):231-44. PubMed ID: 15262415
[TBL] [Abstract][Full Text] [Related]
19. Effect of polyethylene glycol (PEG) chain organization on the physicochemical properties of poly(D, L-lactide) (PLA) based nanoparticles.
Essa S; Rabanel JM; Hildgen P
Eur J Pharm Biopharm; 2010 Jun; 75(2):96-106. PubMed ID: 20211727
[TBL] [Abstract][Full Text] [Related]
20. Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: influence on physical stability and in vitro cell uptake.
De Jaeghere F; Allémann E; Leroux JC; Stevels W; Feijen J; Doelker E; Gurny R
Pharm Res; 1999 Jun; 16(6):859-66. PubMed ID: 10397606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
